(S)-ropivacaine
Also known as 1-propyl-2',6'-pipecoloxylidide, AL-381, LEA-103, (S)-(-)-1-propyl-2',6'-pipecoloxylidide, L-N-n-propylpipecolic acid-2,6-xylidide, (-)-1-propyl-2',6'-pipecoloxylidide, (-)-1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide, (S)-(−)-1-propyl-2',6'-pipecoloxylidide
Ropivacaine (rINN) is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the brand name Naropin.
Key facts
- Drug.verifiedrevid
- 464383595
- Drug.image
- Ropivacaine.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Ropivacaine-from-xtal-3D-bs-17.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Naropin, Rocaine
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Parenteral
- Drug.ATC_prefix
- N01
- Drug.ATC_suffix
- BB09
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.bioavailability
Article
7 sectionsContents
- History
- Clinical use
- Contraindications
- Adverse effects
- Postarthroscopic glenohumeral chondrolysis
- Treatment of overdose
- References
Ropivacaine (rINN) is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the brand name Naropin.
==History== Ropivacaine was developed after bupivacaine was noted to be associated with cardiac arrest, particularly in pregnant women. Ropivacaine was found to have less cardiotoxicity than bupivacaine in animal models.